Effect of bromelain on periodontal destruction and alveolar bone in rats with experimental periodontitis

Int Immunopharmacol. 2023 Aug:121:110446. doi: 10.1016/j.intimp.2023.110446. Epub 2023 Jun 7.

Abstract

Purpose: Several substances that have anti-inflammatory, antiproteinase, and anti-infective properties have been evaluated as modulators of the inflammatory response in periodontal disease. However, evidence for the anti-inflammatory and antioxidative activities of bromelain is limited. This study evaluated the impact of systemically administered bromelain on the progression of experimental periodontitis.

Methods: Four equal groups of 32 Wistar albino rats were created as follows (n = 8): control, periodontitis + saline, periodontitis + 5 mg/kg/day bromelain, and periodontitis + 10 mg/kg/day bromelain. To quantify the resorption of bone and bone volume/tissue volume, bone surface / bone volume, and connectivity, lower jawbones were fixed and then scanned using microcomputed tomography (micro CT). Blood samples were taken to measure the macrophage colony-stimulating factor(M-CSF) concentrations, receptor activator of nuclear factor kappa-Β ligand (RANKL), osteoprotegerin (OPG), tumor necrosis factor-alpha (TNF-α), matrix metalloproteinase-8 (MMP-8), interleukin-6(IL-6), glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA). Histopathological assessments were made to examine the tissue.

Results: Treatment with bromelain improved the healing of the periodontium by decreasing the number of leukocytes and ligament deterioration in the gingival connective tissue and by supporting reintegration with alveolar bone. Bromelain used in ligature-induced periodontitis reduced alveolar bone (AB) resorption as measured by microCT; reduced inflammatory parameters such as IL-6 and TNF-α; regulated oxidative-antioxidative processes by increasing GPx and SOD and reducing MDA levels; and regulated AB modeling by decreasing M-CSF, RANKL, and MMP-8 and increasing OPG levels.

Conclusion: Bromelain may be an option in periodontal therapy by regulating cytokine levels, improving the healing process, and reducing bone resorption and oxidative stress.

Keywords: Alveolar bone loss; Antioxidant; Bromelain; Periodontal diseases; Rats.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / therapeutic use
  • Antioxidants / therapeutic use
  • Bone and Bones / pathology
  • Bromelains / therapeutic use
  • Glutathione Peroxidase
  • Interleukin-6 / therapeutic use
  • Macrophage Colony-Stimulating Factor
  • Matrix Metalloproteinase 8*
  • Periodontitis* / drug therapy
  • Rats
  • Rats, Wistar
  • Tumor Necrosis Factor-alpha
  • X-Ray Microtomography

Substances

  • Matrix Metalloproteinase 8
  • Macrophage Colony-Stimulating Factor
  • Tumor Necrosis Factor-alpha
  • Interleukin-6
  • Bromelains
  • Antioxidants
  • Anti-Inflammatory Agents
  • Glutathione Peroxidase